HRP20110359T1 - Upotreba derivata 3-feniltio-1h-indol-1-octene kiseline kao modulatora crth2 receptorske aktivnosti - Google Patents
Upotreba derivata 3-feniltio-1h-indol-1-octene kiseline kao modulatora crth2 receptorske aktivnosti Download PDFInfo
- Publication number
- HRP20110359T1 HRP20110359T1 HR20110359T HRP20110359T HRP20110359T1 HR P20110359 T1 HRP20110359 T1 HR P20110359T1 HR 20110359 T HR20110359 T HR 20110359T HR P20110359 T HRP20110359 T HR P20110359T HR P20110359 T1 HRP20110359 T1 HR P20110359T1
- Authority
- HR
- Croatia
- Prior art keywords
- indole
- acetic acid
- crth2
- methyl
- treatment
- Prior art date
Links
- ZDMDGBTZFRGEKV-UHFFFAOYSA-N 2-(3-phenylsulfanylindol-1-yl)acetic acid Chemical class C12=CC=CC=C2N(CC(=O)O)C=C1SC1=CC=CC=C1 ZDMDGBTZFRGEKV-UHFFFAOYSA-N 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 9
- 201000010099 disease Diseases 0.000 claims abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 7
- 230000001404 mediated effect Effects 0.000 claims abstract 7
- MBDUIEKYVPVZJH-UHFFFAOYSA-N 1-ethylsulfonylethane Chemical group CCS(=O)(=O)CC MBDUIEKYVPVZJH-UHFFFAOYSA-N 0.000 claims abstract 3
- NICDUWDZPNAQNH-UHFFFAOYSA-N chloro-[chloro(methoxy)methyl]sulfonyl-methoxymethane Chemical group COC(Cl)S(=O)(=O)C(Cl)OC NICDUWDZPNAQNH-UHFFFAOYSA-N 0.000 claims abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 239000012453 solvate Substances 0.000 claims abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 239000001257 hydrogen Substances 0.000 claims abstract 2
- PLHWKTXZRRUSCX-UHFFFAOYSA-N 2-[4-acetamido-2-methyl-3-(4-methylsulfonylphenyl)sulfanylindol-1-yl]acetic acid Chemical compound C1=2C(NC(=O)C)=CC=CC=2N(CC(O)=O)C(C)=C1SC1=CC=C(S(C)(=O)=O)C=C1 PLHWKTXZRRUSCX-UHFFFAOYSA-N 0.000 claims 1
- BXSDULPHPLBIRO-UHFFFAOYSA-N 2-[4-acetamido-3-(2-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid Chemical compound C1=2C(NC(=O)C)=CC=CC=2N(CC(O)=O)C(C)=C1SC1=CC=CC=C1Cl BXSDULPHPLBIRO-UHFFFAOYSA-N 0.000 claims 1
- HALVQXLHSWSFJM-UHFFFAOYSA-N 2-[4-acetamido-3-(3-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid Chemical compound C1=2C(NC(=O)C)=CC=CC=2N(CC(O)=O)C(C)=C1SC1=CC=CC(Cl)=C1 HALVQXLHSWSFJM-UHFFFAOYSA-N 0.000 claims 1
- IFNCJLZZWYUVEE-UHFFFAOYSA-N 2-[4-acetamido-3-(4-ethylsulfonylphenyl)sulfanyl-2-methylindol-1-yl]acetic acid Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1SC1=C(C)N(CC(O)=O)C2=CC=CC(NC(C)=O)=C12 IFNCJLZZWYUVEE-UHFFFAOYSA-N 0.000 claims 1
- GIKLOMGMVNCZNU-UHFFFAOYSA-N 2-[5-acetamido-3-(4-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid Chemical compound C12=CC(NC(=O)C)=CC=C2N(CC(O)=O)C(C)=C1SC1=CC=C(Cl)C=C1 GIKLOMGMVNCZNU-UHFFFAOYSA-N 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Spoj formule (I), ili njegova farmaceutski prihvatljiva sol ili solvat, naznačen time da je za liječenje bolesti posredovane s CRTh2: gdje: R1 je NHCOMe; R2 je C1-6alkil ili vodik; iR3 je fenil proizvoljno supstituiran sa kloro, metoksi, metilsulfonom ili etilsulfonom. Patent sadrži još 6 patentnih zahtjeva.
Claims (7)
1. Spoj formule (I), ili njegova farmaceutski prihvatljiva sol ili solvat, naznačen time da je za liječenje bolesti posredovane s CRTh2:
[image]
gdje:
R1 je NHCOMe;
R2 je C1-6alkil ili vodik; i
R3 je fenil proizvoljno supstituiran sa kloro, metoksi, metilsulfonom ili etilsulfonom.
2. Spoj prema zahtjevu 1 naznačen time da je za liječenje bolesti posredovane s CRTh2 gdje R2 je metil.
3. Spoj prema zahtjevu 1 ili 2 naznačen time da je za liječenje bolesti posredovane s CRTh2 gdje R3 je fenil proizvoljno supstituiran sa kloro, metoksi, metilsulfonom ili etilsulfonom na 4. položaju.
4. Spoj prema zahtjevu 1 ili 2 naznačen time da je za liječenje bolesti posredovane s CRTh2 gdje je spoj prema formuli (I) odabran od:
5-(acetilamino)-3-[(4-klorofenil)tio]-2-metil-1H-indol-1-octene kiseline;
4-(acetilamino)-3-[(3-klorofenil)tio]-2-metil-1H-indol-1-octene kiseline;
4-(acetilamino)-2-metil-3-[[4-(metilsulfonil)fenil]tio]-1H-indol-1-octene kiseline;
4-(acetilamino)-3-[(2-klorofenil)tio]-2-metil-1H-indol-1-octene kiseline; i
4-(acetilamino)-2-metil-3-[[4-(etilsulfonil)fenil]tio]-1H-indol-1-octene kiseline;
i njihovih farmaceutski prihvatljivih soli i solvata.
5. Spoj prema bilo kojem od zahtjeva 1 do 4 naznačen time da je za liječenje bolesti posredovanih sa CRTh2 gdje je bolest posredovana sa CRTh2 astma.
6. Spoj formule (I) kako je definiran u bilo kojem od zahtjeva 1 do 4 naznačen time da se koristi kod terapije.
7. Farmaceutski pripravak koji sadrži spoj formule (I) kako je definiran u bilo kojem od zahtjeva 1 do 4 naznačen time da je u kombinaciji sa farmaceutski prihvatljivim pomoćnim sredstvom, razrjeđivačem ili nosačem.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0301569A SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Novel compounds |
| SE0302305A SE0302305D0 (sv) | 2003-05-27 | 2003-08-27 | Novel Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110359T1 true HRP20110359T1 (hr) | 2011-06-30 |
Family
ID=33492578
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090281T HRP20090281T1 (hr) | 2003-05-27 | 2009-05-15 | 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti |
| HR20110359T HRP20110359T1 (hr) | 2003-05-27 | 2011-05-16 | Upotreba derivata 3-feniltio-1h-indol-1-octene kiseline kao modulatora crth2 receptorske aktivnosti |
| HRP20120390TT HRP20120390T1 (hr) | 2003-05-27 | 2012-05-10 | Intermedijarni spoj etil estera 4-(acetilamino)-3-[(4-klorofenil)tio]-2-metil-1h-indol-1-octene kiseline |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090281T HRP20090281T1 (hr) | 2003-05-27 | 2009-05-15 | 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120390TT HRP20120390T1 (hr) | 2003-05-27 | 2012-05-10 | Intermedijarni spoj etil estera 4-(acetilamino)-3-[(4-klorofenil)tio]-2-metil-1h-indol-1-octene kiseline |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US7687535B2 (hr) |
| EP (3) | EP2281815B1 (hr) |
| JP (2) | JP4541361B2 (hr) |
| KR (3) | KR20110050754A (hr) |
| CN (2) | CN1795174B (hr) |
| AR (1) | AR044552A1 (hr) |
| AT (3) | ATE552243T1 (hr) |
| AU (1) | AU2004242624B2 (hr) |
| BR (1) | BRPI0410711B8 (hr) |
| CA (1) | CA2526866C (hr) |
| CO (1) | CO5630030A2 (hr) |
| CY (3) | CY1109104T1 (hr) |
| DE (2) | DE602004020072D1 (hr) |
| DK (3) | DK2025670T3 (hr) |
| ES (3) | ES2382606T3 (hr) |
| HK (3) | HK1090635A1 (hr) |
| HR (3) | HRP20090281T1 (hr) |
| IL (4) | IL171928A (hr) |
| IS (2) | IS2722B (hr) |
| MX (1) | MXPA05012680A (hr) |
| MY (1) | MY144483A (hr) |
| NO (1) | NO20056130L (hr) |
| NZ (1) | NZ543722A (hr) |
| PL (3) | PL2025670T3 (hr) |
| PT (3) | PT2025670E (hr) |
| RU (1) | RU2361860C2 (hr) |
| SE (2) | SE0301569D0 (hr) |
| SI (3) | SI1656346T1 (hr) |
| TW (2) | TWI328004B (hr) |
| WO (1) | WO2004106302A1 (hr) |
| ZA (1) | ZA200509598B (hr) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| SE0302232D0 (sv) * | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| BRPI0508540B8 (pt) | 2004-03-11 | 2021-05-25 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica, e, uso de um composto |
| DK1833791T3 (da) | 2004-12-27 | 2011-10-24 | Actelion Pharmaceuticals Ltd | 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister |
| GB0500604D0 (en) * | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
| DOP2006000016A (es) * | 2005-01-26 | 2006-07-31 | Aventis Pharma Inc | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2. |
| AU2006237365B2 (en) | 2005-04-21 | 2012-09-20 | Merck Serono Sa | 2,3 substituted pyrazine sulfonamides as inhibitors of CRTH2 |
| EP1891075B1 (en) | 2005-05-24 | 2011-10-19 | Merck Serono SA | Tricyclic spiro derivatives as crth2 modulators |
| EP1911759A4 (en) | 2005-07-22 | 2010-07-21 | Shionogi & Co | AZAINDOL DERIVATIVE ANTAGONISTIC EFFECT ON PGD2 RECEPTOR |
| ES2372701T3 (es) | 2005-07-22 | 2012-01-25 | Shionogi & Co., Ltd. | Derivado de indol que tiene actividad antagonista del receptor de pgd2. |
| RU2405770C2 (ru) | 2005-09-27 | 2010-12-10 | Сионоги Энд Ко., Лтд. | Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2 |
| WO2007036743A2 (en) * | 2005-09-30 | 2007-04-05 | Argenta Discovery Limited | Quinolines and their therapeutic use |
| CN101454284A (zh) * | 2006-05-26 | 2009-06-10 | 阿斯利康(瑞典)有限公司 | 联芳基或芳基-杂芳基取代的吲哚类化合物 |
| WO2013142295A1 (en) | 2012-03-21 | 2013-09-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulating hair growth |
| EP3175856A1 (en) | 2006-06-16 | 2017-06-07 | The Trustees of the University of Pennsylvania | Methods and compositions for inhibiting or reducing hair loss |
| KR20090042808A (ko) * | 2006-07-22 | 2009-04-30 | 옥사겐 리미티드 | 씨알티에이치2 길항제 활성을 갖는 화합물 |
| DK2051962T3 (da) | 2006-08-07 | 2012-01-02 | Actelion Pharmaceuticals Ltd | (3-amino-1,2,3,4-tetrahydro-9H-carbazol-9-yl)-eddikesyrederivater |
| GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
| WO2008156780A1 (en) * | 2007-06-21 | 2008-12-24 | Actimis Pharmaceuticals, Inc. | Particulates of a crth2 antagonist |
| MY149005A (en) * | 2007-06-21 | 2013-06-28 | Actimis Pharmaceuticals Inc | Amine salts of a crth2 antagonist |
| PL2229358T3 (pl) | 2007-12-14 | 2011-09-30 | Pulmagen Therapeutics Asthma Ltd | Związki indolowe i ich zastosowanie terapeutyczne |
| US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| WO2010039982A1 (en) * | 2008-10-01 | 2010-04-08 | Ironwood Pharmaceuticals, Inc. | Crth2 modulators |
| EP2396295A1 (en) | 2009-02-12 | 2011-12-21 | Merck Serono S.A. | Phenoxy acetic acid derivatives |
| CA2767132C (en) * | 2009-07-06 | 2017-06-20 | Astrazeneca Ab | Intermediates and processes for the preparation of 4-(acetylamino))-3-[(4-chloro-phenyl)thio]-2-methyl-1h-indole-1-acetic acid |
| GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| US9032565B2 (en) | 2009-12-16 | 2015-05-19 | Kohler Co. | Touchless faucet assembly and method of operation |
| WO2011073662A1 (en) | 2009-12-17 | 2011-06-23 | Astrazeneca Ab | Combination of a benzoxazinone and a further agent for treating respiratory diseases |
| BR112012024114B1 (pt) | 2010-03-22 | 2021-02-09 | Idorsia Pharmaceuticals Ltd | Compostos derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9h-carbazol, uso dos mesmos, e, composição farmacêutica |
| GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| PL2697223T3 (pl) | 2011-04-14 | 2017-01-31 | Actelion Pharmaceuticals Ltd. | Pochodne kwasu 7-(heteroaryloamino)-6,7,8,9-tetrahydropirydo[1,2-a]indolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny D2 |
| AU2012351342A1 (en) | 2011-12-16 | 2014-07-24 | Atopix Therapeutics Limited | Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| EP2903615B1 (en) * | 2012-10-05 | 2021-04-07 | Merck Sharp & Dohme Corp. | 5-pyridin-3-yl-2,3-dihydro-1h-indole derivatives as aldosterone synthase (cyp11b2) inhibitors for the treatment of hypertension |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| CN105073747B (zh) * | 2013-03-15 | 2017-06-06 | 普莱希科公司 | 杂环化合物及其应用 |
| EP3004083A4 (en) * | 2013-05-24 | 2016-11-16 | California Inst Biomedical Res | COMPOUNDS FOR THE TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS |
| BR112016021471B1 (pt) | 2014-03-17 | 2022-10-11 | Idorsia Pharmaceuticals Ltd | Compostos derivados de ácido acético azaindol, composição farmacêutica, e, uso de um composto |
| CA2938107A1 (en) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
| EP3256121B1 (en) | 2015-02-13 | 2024-08-07 | INSERM - Institut National de la Santé et de la Recherche Médicale | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
| ES2947824T3 (es) | 2015-07-30 | 2023-08-21 | Univ Pennsylvania | Alelos polimórficos de un solo nucleótido del gen DP-2 humano para la detección de la susceptibilidad a la inhibición del crecimiento del cabello por antagonistas de PGD2 |
| KR20180053345A (ko) | 2015-09-15 | 2018-05-21 | 이도르시아 파마슈티컬스 리미티드 | 결정질 형태 |
| WO2019075243A1 (en) | 2017-10-13 | 2019-04-18 | Plexxikon Inc. | SOLID FORMS OF A COMPOUND FOR MODULATING KINASES |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
| JPH0615542B2 (ja) | 1986-07-22 | 1994-03-02 | 吉富製薬株式会社 | ピラゾロピリジン化合物 |
| US5095031A (en) * | 1990-08-20 | 1992-03-10 | Abbott Laboratories | Indole derivatives which inhibit leukotriene biosynthesis |
| WO1993005020A1 (en) | 1991-09-06 | 1993-03-18 | Merck & Co., Inc. | Indoles as inhibitors of hiv reverse transcriptase |
| FR2692574B1 (fr) | 1992-06-23 | 1995-06-23 | Sanofi Elf | Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles. |
| CN1119856A (zh) | 1993-02-24 | 1996-04-03 | 麦克公司 | Hiv逆转录酶抑制剂 |
| US5486525A (en) | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
| US5567711A (en) * | 1995-04-19 | 1996-10-22 | Abbott Laboratories | Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| KR19990082463A (ko) | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체 |
| ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
| TW472045B (en) | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| WO1999009007A1 (en) | 1997-08-21 | 1999-02-25 | American Home Products Corporation | Solid phase synthesis of 2,3-disubstituted indole compounds |
| ATE239013T1 (de) | 1997-12-19 | 2003-05-15 | Lilly Co Eli | Hypoglykamische imidazoline derivate |
| US6916841B2 (en) * | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| AU5886500A (en) | 1999-06-23 | 2001-01-09 | Sepracor, Inc. | Indolyl-benzimidazole antibacterials, and methods of use thereof |
| WO2001032621A1 (fr) * | 1999-10-29 | 2001-05-10 | Wakunaga Pharmaceutical Co., Ltd. | Nouveaux derives d'indole, et medicaments contenant lesdits derives comme principe actif |
| MXPA02006338A (es) | 1999-12-24 | 2002-12-13 | Aventis Pharma Ltd | Azaindoles. |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| US6878522B2 (en) * | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| JP4595182B2 (ja) * | 2000-09-07 | 2010-12-08 | ソニー株式会社 | 情報記録装置、情報再生装置、情報記録方法、情報再生方法、および情報記録媒体、並びにプログラム提供媒体 |
| TWI317634B (en) * | 2001-12-13 | 2009-12-01 | Nat Health Research Institutes | Aroyl indoles compounds |
| KR100656037B1 (ko) | 2002-02-01 | 2006-12-11 | 에프. 호프만-라 로슈 아게 | 알파-1 작용제인 치환된 인돌 |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| EP2423190A1 (en) | 2002-05-16 | 2012-02-29 | Shionogi&Co., Ltd. | Compounds Exhibiting PGD 2 Receptor Antagonism |
| SE0201635D0 (sv) * | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| SE0301569D0 (sv) * | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
| SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| RU2006109108A (ru) * | 2003-10-14 | 2007-11-20 | Оксаген Лимитед (GB) | Соединения, обладающие активностью антагонистов crth2 рецепторов |
| SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| GB0500604D0 (en) * | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
| GB2422831A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
| CN101454284A (zh) | 2006-05-26 | 2009-06-10 | 阿斯利康(瑞典)有限公司 | 联芳基或芳基-杂芳基取代的吲哚类化合物 |
| AU2007256564A1 (en) | 2006-06-08 | 2007-12-13 | Neurokey A/S | Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia |
| CA2656150A1 (en) | 2006-06-28 | 2008-01-03 | Sanofi-Aventis | New cxcr2 inhibitors |
-
2003
- 2003-05-27 SE SE0301569A patent/SE0301569D0/xx unknown
- 2003-08-27 SE SE0302305A patent/SE0302305D0/xx unknown
-
2004
- 2004-05-19 TW TW093114113A patent/TWI328004B/zh not_active IP Right Cessation
- 2004-05-19 TW TW099109193A patent/TW201024261A/zh unknown
- 2004-05-24 AR ARP040101792A patent/AR044552A1/es unknown
- 2004-05-25 DE DE602004020072T patent/DE602004020072D1/de not_active Expired - Lifetime
- 2004-05-25 EP EP10180348A patent/EP2281815B1/en not_active Expired - Lifetime
- 2004-05-25 PT PT08165755T patent/PT2025670E/pt unknown
- 2004-05-25 NZ NZ543722A patent/NZ543722A/xx not_active IP Right Cessation
- 2004-05-25 EP EP04734774A patent/EP1656346B1/en not_active Expired - Lifetime
- 2004-05-25 JP JP2006532212A patent/JP4541361B2/ja not_active Expired - Fee Related
- 2004-05-25 ES ES10180348T patent/ES2382606T3/es not_active Expired - Lifetime
- 2004-05-25 AT AT10180348T patent/ATE552243T1/de active
- 2004-05-25 KR KR1020117009790A patent/KR20110050754A/ko not_active Application Discontinuation
- 2004-05-25 RU RU2005137403/04A patent/RU2361860C2/ru active
- 2004-05-25 PT PT04734774T patent/PT1656346E/pt unknown
- 2004-05-25 US US10/558,228 patent/US7687535B2/en active Active
- 2004-05-25 SI SI200431120T patent/SI1656346T1/sl unknown
- 2004-05-25 CN CN2004800146027A patent/CN1795174B/zh not_active Expired - Fee Related
- 2004-05-25 PL PL08165755T patent/PL2025670T3/pl unknown
- 2004-05-25 KR KR1020057022513A patent/KR101067586B1/ko active IP Right Grant
- 2004-05-25 WO PCT/SE2004/000808 patent/WO2004106302A1/en active Application Filing
- 2004-05-25 AU AU2004242624A patent/AU2004242624B2/en not_active Ceased
- 2004-05-25 PT PT10180348T patent/PT2281815E/pt unknown
- 2004-05-25 KR KR1020117009788A patent/KR101067535B1/ko not_active IP Right Cessation
- 2004-05-25 PL PL04734774T patent/PL1656346T3/pl unknown
- 2004-05-25 CA CA2526866A patent/CA2526866C/en not_active Expired - Fee Related
- 2004-05-25 DK DK08165755.3T patent/DK2025670T3/da active
- 2004-05-25 SI SI200431874T patent/SI2281815T1/sl unknown
- 2004-05-25 AT AT04734774T patent/ATE425965T1/de active
- 2004-05-25 ES ES08165755T patent/ES2361485T3/es not_active Expired - Lifetime
- 2004-05-25 MY MYPI20041992A patent/MY144483A/en unknown
- 2004-05-25 ES ES04734774T patent/ES2322650T3/es not_active Expired - Lifetime
- 2004-05-25 DK DK10180348.4T patent/DK2281815T3/da active
- 2004-05-25 DK DK04734774T patent/DK1656346T3/da active
- 2004-05-25 DE DE602004031894T patent/DE602004031894D1/de not_active Expired - Lifetime
- 2004-05-25 SI SI200431669T patent/SI2025670T1/sl unknown
- 2004-05-25 BR BRPI0410711A patent/BRPI0410711B8/pt not_active IP Right Cessation
- 2004-05-25 PL PL10180348T patent/PL2281815T3/pl unknown
- 2004-05-25 CN CN2011102633202A patent/CN102391171A/zh active Pending
- 2004-05-25 MX MXPA05012680A patent/MXPA05012680A/es active IP Right Grant
- 2004-05-25 AT AT08165755T patent/ATE502010T1/de active
- 2004-05-25 EP EP08165755A patent/EP2025670B1/en not_active Expired - Lifetime
-
2005
- 2005-11-14 IL IL171928A patent/IL171928A/en not_active IP Right Cessation
- 2005-11-23 CO CO05118882A patent/CO5630030A2/es active IP Right Grant
- 2005-11-28 ZA ZA200509598A patent/ZA200509598B/en unknown
- 2005-12-20 IS IS8189A patent/IS2722B/is unknown
- 2005-12-22 NO NO20056130A patent/NO20056130L/no not_active Application Discontinuation
-
2006
- 2006-10-11 HK HK06111158.9A patent/HK1090635A1/xx not_active IP Right Cessation
-
2008
- 2008-10-23 IL IL194872A patent/IL194872A0/en unknown
-
2009
- 2009-03-04 US US12/397,618 patent/US20090163518A1/en not_active Abandoned
- 2009-05-15 HR HR20090281T patent/HRP20090281T1/hr unknown
- 2009-05-28 CY CY20091100564T patent/CY1109104T1/el unknown
- 2009-06-30 HK HK09105852.7A patent/HK1126773A1/xx not_active IP Right Cessation
- 2009-06-30 HK HK11107570.0A patent/HK1149563A1/xx not_active IP Right Cessation
-
2010
- 2010-03-31 JP JP2010082748A patent/JP2010155862A/ja active Pending
- 2010-08-09 IS IS8920A patent/IS8920A/is unknown
-
2011
- 2011-03-14 US US13/047,280 patent/US20110263614A1/en not_active Abandoned
- 2011-04-11 IL IL212265A patent/IL212265A0/en unknown
- 2011-04-14 IL IL212371A patent/IL212371A0/en unknown
- 2011-05-16 HR HR20110359T patent/HRP20110359T1/hr unknown
- 2011-05-16 CY CY20111100464T patent/CY1111469T1/el unknown
-
2012
- 2012-01-05 US US13/344,051 patent/US20120178764A1/en not_active Abandoned
- 2012-05-10 HR HRP20120390TT patent/HRP20120390T1/hr unknown
- 2012-05-29 CY CY20121100486T patent/CY1112853T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110359T1 (hr) | Upotreba derivata 3-feniltio-1h-indol-1-octene kiseline kao modulatora crth2 receptorske aktivnosti | |
| AR077485A2 (es) | Difenilureas substituidas con carboxiarilo como inhibidores de raf quinasa | |
| PE20091005A1 (es) | N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas | |
| TW200745029A (en) | Sulfonamide derivatives exhibiting PGD2 receptor antagonism | |
| HRP20090162T1 (hr) | Kinolinon-karboksamidni spojevi kao agonisti 5-ht4 receptora | |
| CA2495880A1 (en) | Pyrimidine derivatives and their use as cb2 modulators | |
| HRP20060100T3 (hr) | Derivati diaril i arilheteroaril uree kao modulatori 5-ht2a serotonin receptora korisni za profilaksu i liječenje poremećaja povezanih s njima | |
| WO2005028445A3 (en) | Derivatives of n-(1h-indazolyl)- and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for the treatment of pain | |
| RU2006105717A (ru) | Производные пиперазина и их применение в качестве терапевтических агентов | |
| DE60204674D1 (de) | Retinoid x rezeptormodulatoren | |
| HRP20080052T3 (hr) | Derivati tropana supstituirani imidazopiridinom santagonističkim djelovanjem na ccr5 receptor za liječenje hiv-a i upala | |
| JP2004516293A5 (hr) | ||
| RU2008125196A (ru) | Новые производные тиофена | |
| NO20045103L (no) | Benzofuserte heteroarylamid-derivater av thienopyridiner anvendelige som terapeutiske midler, farmasoytiske blandinger omfattende de samme og fremgangsmater for deres anvendelse | |
| RS50698B (sr) | 3-FENIL-PIRAZOL DERIVATI KAO MODULATORI 5-HT-2a SEROTONIN RECEPTORA KORISNI ZA LEČENJE SA TIM POVEZANIH POREMEĆAJA | |
| ATE420859T1 (de) | Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren | |
| MXPA03010445A (es) | Derivados de 4(fenil-piperazinil-metil) benzamida y su uso para tratamiento del dolor, ansiedad o trastornos gastrointestinales. | |
| EA200802173A1 (ru) | Производные терфенила для лечения болезни альцгеймера | |
| AR056574A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
| JP2006516626A5 (hr) | ||
| RU2005122615A (ru) | Соединения n-(индолэтил)циклоамина | |
| PE20050329A1 (es) | Derivados de nicotinamida como inhibidores de fosfodiesterasa pde4 | |
| EE05035B1 (et) | 1-[fenüül-(8-kinolinüül)metüül]piperasiini derivaadid ning nende kasutamine meditsiinis | |
| RU2007141412A (ru) | Пиридилдиметилсульфоновое производное |